Role of the Renin-Angiotensin System in Glucose Homeostasis

肾素-血管紧张素系统在血糖稳态中的作用

• 批准号: 10665042
• 负责人: Sakeneh Zraika
• 金额: $ 39.05万
• 依托单位: SEATTLE INST FOR BIOMEDICAL/CLINICAL RES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-14 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10665042
• 关键词: Address; Adolescent; Adult; Anabolism; Angiotensins; Antidiabetic Drugs; Apoptosis; Beta Cell; Binding; CRISPR/Cas technology; Cell Death; Cell Proliferation; Cell Survival; Cell physiology; Cells; Clinical Management; Data; Deterioration; Development; Diabetic mouse; Dipeptides; Diphtheria Toxin; Exposure to; Failure; Future; GLP-I receptor; GPRC6A gene; Genetic Transcription; Glucagon; Glucose; Goals; Human; Hydrolysis; In Vitro; Inhibition of Apoptosis; Insulin; Investigation; Islets of Langerhans Transplantation; Knock-out; Mediating; Modeling; Mus; Mutagenesis; Natural regeneration; Non-Insulin-Dependent Diabetes Mellitus; Output; Paracrine Communication; Pharmaceutical Preparations; Prevalence; Production; Proliferating; Property; Proteins; Public Health; Renin-Angiotensin System; Research; Resistance; Role; Signal Pathway; Signal Transduction; Structure of beta Cell of islet; Testing; Therapeutic; Therapeutic Intervention; Time; Withdrawal; Youth; active method; age related; blood glucose regulation; cell regeneration; diabetic; gain of function; glucagon-like peptide 1; glycemic control; improved; in vivo; inhibitor; innovation; insulin secretion; islet; loss of function; new therapeutic target; non-diabetic; novel; paracrine; phosphoproteomics; preservation; prevent; proglucagon; protective effect; targeted treatment; therapeutic development; transplant model

PROJECT SUMMARY/ABSTRACT In treating type 2 diabetes (T2D), there is a paucity of medications simultaneously targeting deficits in both β-cell function and mass. Angiotensin(1-7), a metabolite of the renin-angiotensin system, may fill this gap; however, its underlying mechanisms of action are incompletely understood. Our data reveal that the insulinotropic action of angiotensin(1-7) is dependent on its hydrolysis to the dipeptide, angiotensin(1-2), the latter also conveying pro-survival and proliferative effects in β cells. Angiotensin(1-2) activates G-protein- coupled receptor family C group 6 member A (GPRC6A), which we show is expressed in islet a cells. Further, angiotensin(1-2) increases a cell-derived glucagon-like peptide-1 (GLP-1) release, suggesting it acts via GPRC6A on the a cell to promote insulin secretion in a paracrine fashion. Indeed, in GLP-1 receptor deficient islets, we find that angiotensin(1-2) fails to potentiate insulin secretion; however, its ability to enhance β-cell survival and proliferation is retained. The latter suggests angiotensin(1-2)’s action is, in part, GLP-1 receptor- independent. Based on these novel data, we hypothesize angiotensin(1-2) enhances β-cell function via intra- islet paracrine signaling, and promotes β-cell survival/proliferation via a novel GLP-1-independent mechanism. The following specific aims address this hypothesis, with the goal of improving treatment options in T2D: Specific Aim 1. To determine the mechanism by which angiotensin(1-2) increases islet-derived GLP-1 and insulin secretion. Mice (in vivo) and islets (in vitro) with diphtheria toxin-induced a-cell destruction or a cell-specific GPRC6A knockout will be used to determine whether angiotensin(1-2)-mediated increases in insulin release require a cells or a-cell GPRC6A, respectively. We will probe mechanisms for increased GLP-1 release, and confirm key findings in human islets with and without GLP-1 receptor or GPRC6A blockade. Specific Aim 2. To identify signaling pathways/proteins mediating the β-cell survival and proliferative effects of Ang(1-2) in human islets. The ability of angiotensin(1-2) to inhibit apoptosis, reduce dedifferentiation and enhance proliferation of β cells will be examined in human islets under non-diabetic and diabetic conditions. The contribution of mechanisms independent of GLP-1 or GPRC6A will be determined. Effectors of angiotensin(1-2) action will be identified using non-biased phosphoproteomics, then loss-/gain-of- function studies in islets will serve as a preliminary screen for effectors that could be targeted therapeutically. Specific Aim 3. To determine whether Ang(1-2) improves human islet function/survival in vivo, and whether hydrolysis of Ang(1-7) is required for its anti-diabetic effects. We will utilize a human islet transplant model to determine the ability of angiotensin(1-2) to improve β-cell function/survival and glycemia in diabetic mice. Further, we will test whether the insulinotropic action of angiotensin(1-7) requires its hydrolysis, as is the case in vitro. The latter is highly significant for clinical management of T2D because it will inform on the utility of hydrolysis-resistant angiotensin(1-7)-based medications currently in development.

项目摘要/摘要 在治疗2型糖尿病（T2D）时，仅针对两者的药物很少 β细胞功能和质量。血管紧张素（1-7）是肾素 - 血管紧张素系统的代谢产物，可能会填补这一空白。 但是，其基本的作用机制尚未完全理解。我们的数据表明 血管紧张素（1-7）的胰岛素性作用取决于其水解为二肽，血管紧张素（1-2），即 后者还传达了β细胞中的促生存和增殖作用。血管紧张素（1-2）激活G蛋白 我们显示的耦合受体家族C 6组成员A（GPRC6A）在胰岛A细胞中表达。此外， 血管紧张素（1-2）增加了细胞来源的胰高血糖素样肽-1（GLP-1）释放，表明它通过 GPRC6A在A细胞上以旁分泌方式促进胰岛素分泌。确实，在GLP-1受体默认 胰岛，我们发现血管紧张素（1-2）无法潜在胰岛素分泌。但是，它增强β细胞的能力 保留生存和增殖。后者表明血管紧张素（1-2）的作用部分是GLP-1受体 - 独立的。基于这些新数据，我们假设血管紧张素（1-2）通过内部增强了β细胞的功能 胰岛旁分泌信号传导，并通过新型GLP-1独立的机制促进β细胞的存活/增殖。 以下具体目的解决了这一假设，目的是改善T2D的治疗选择： 具体目的1。确定血管紧张素（1-2）增加胰岛衍生的GLP-1的机制 和胰岛素分泌。小鼠（体内）和胰岛（体外），毒素毒素诱导的A细胞破坏或A 细胞特异性的GPRC6A敲除将用于确定血管紧张素（1-2）介导的增加 胰岛素释放分别需要细胞或A细胞GPRC6A。我们将探测增加GLP-1的机制 释放，并在具有和没有GLP-1受体或GPRC6A阻滞的人类胰岛中确认关键发现。 具体目标2。鉴定介导β细胞存活和增殖的信号通路/蛋白质 人类胰岛（1-2）的影响。血管紧张素（1-2）抑制凋亡的能力，减少 在非糖尿病和 糖尿病状况。将确定独立于GLP-1或GPRC6A的机制的贡献。 血管紧张素（1-2）作用的效应因子将使用无偏置的磷蛋白组学鉴定，然后损失 - 胰岛中的功能研究将作为可以针对治疗的作用的初步屏幕。 特定目的3。确定ANG（1-2）是否改善了人类胰岛功能/体内生存，并且 ANG的水解是否需要其抗糖尿病作用（1-7）。我们将利用人类胰岛 移植模型确定血管紧张素（1-2）改善β细胞功能/存活和糖脂的能力 糖尿病小鼠。此外，我们将测试血管紧张素（1-7）是否需要其水解， 与体外一样。后者对于T2D的临床管理非常重要，因为它将告知 目前正在开发的基于水解的血管紧张素（1-7）药物的效用。